Roivant says mosliciguat cut pulmonary vascular resistance in Phase 2

Roivant said mosliciguat produced a 56.3% placebo-adjusted reduction in pulmonary vascular resistance in the Phase 2 PHocus study. It also cited a 35.2m 6MWD gain and said Phase 3 is underway.